Triple threat: new combo therapy aims to tackle rare lung disease
NCT ID NCT07266519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a triple combination of three drugs—sotatercept, an endothelin receptor antagonist, and a phosphodiesterase-5 inhibitor—can improve blood flow in the lungs of people newly diagnosed with pulmonary arterial hypertension (PAH). The study will enroll 25 treatment-naïve adults and measure changes in pulmonary vascular resistance after 24 weeks. It is an open-label, single-arm study, meaning everyone gets the same treatment and no placebo is used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sotatercept combined with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor
- What this could lead to
- If successful, this triple-drug combination could become a new standard first treatment for pulmonary arterial hypertension, potentially improving blood flow and symptoms better than current options.
- What could go wrong
- This is a small, early-phase study with only 25 people and no comparison group. Results may not apply to all patients, and side effects from combining three drugs are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check